Full-Time

Senior Scientist 2

Computational Discovery Science

Posted on 9/9/2026

Tempus

Tempus

1,001-5,000 employees

AI-driven platform for medical data insights

Compensation Overview

$145k - $190k/yr

+ Incentive compensation + Restricted stock units

Company Historically Provides H1B Sponsorship

Redwood City, CA, USA + 1 more

More locations: New York, NY, USA

In Person

PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Scikit-learn
Python
Data Science
R
Git
SQL
Machine Learning
Docker
AWS
Pandas
NumPy

Get referred to Tempus

See people who can refer or advise you

Requirements
  • A PhD in a quantitative discipline such as Bioinformatics, Computational Biology, or Data Science, or in Life Sciences with a strong computational publication record.
  • At least 4 years of work experience leveraging genomic and multimodal data with machine learning approaches to address questions in complex diseases, especially cancer.
  • Proficiency in R, Python, and SQL.
  • Strong understanding of cancer, genomics, and/or immunology.
  • Extensive experience analyzing genomic data and running statistical and machine learning models.
  • Excellent written and verbal communication skills, with the ability to present complex information clearly and persuasively to diverse audiences.
  • Experience leading multidisciplinary project teams and the ability to lead complex projects.
Responsibilities
  • Utilize novel analytical methods applied to multimodal genomic, imaging, and clinical data to identify targets in patient sub-populations.
  • Apply in silico methodologies to Tempus Real-World Data to identify molecular, biological, and clinical patterns associated with specific patient populations.
  • Leverage multimodal data to create joint embeddings, enabling robust clustering of patients and identification of novel molecular subtypes.
  • Utilize the LLM-orchestrated Tempus Loop Agent architecture to autonomously prioritize targets.
  • Partner with the modeling lab to use data from CRISPR and cell perturbation experiments in patient-derived organoids to identify and validate novel targets.
  • Independently execute complex translational or real-world evidence research projects integrating molecular and clinical data from the Tempus multimodal data platform.
  • Work closely with cross-functional teams across R&D and the broader organization, including product engineering, clinical genomics labs, data science, and medical teams.
  • Communicate scientific and technical plans and outcomes to project and senior leadership stakeholders, internal teams, and external partners.
  • Present scientific findings clearly and meaningfully to external stakeholders and non-technical audiences.
  • Author abstracts, posters, and peer-reviewed publications illustrating the value of multimodal analysis and artificial intelligence in drug discovery.
Desired Qualifications
  • Familiarity with patient-derived organoid models for target identification and validation, biomarker discovery, and identifying a drug’s mechanism of action or preclinical proof of concept.
  • Experience with early-stage drug development, including target discovery and biomarker identification.
  • Experience analyzing single-cell RNA sequencing and spatial transcriptomics.
  • Proficiency with computational biology packages and environments including Pandas, NumPy, SciPy, Scikit-learn, Jupyter Notebooks, RStudio, tidyverse, ggplot, Git, Docker, and AWS.
  • Experience with R package development.
  • Comfort in a client-facing role with prior consulting and/or client-facing experience.
  • Ability to thrive in a fast-paced environment and shift priorities seamlessly.

Tempus provides an AI-powered platform that analyzes medical data and images to help physicians improve patient care and supports drug development for pharmaceutical and biotech companies. The platform produces actionable insights, finds gaps in care, and helps identify personalized therapy options for patients, while researchers use it for drug target discovery and evaluating treatments. It differentiates itself with a proprietary data-and-imaging platform paired with cancer-focused research tools, including a pan-cancer organoid platform and a validated liquid biopsy assay for profiling circulating tumor DNA. Its goal is to improve patient outcomes through data-driven, personalized medicine and to speed cancer research and development.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Get referred to Tempus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $382.5 million, up 22%; guidance rose to $1.605 billion.
  • July 2026 signed about $200 million in new data licenses, strengthening higher-margin recurring revenue.
  • August 24, 2026 FDA-cleared ECG-PH expands Tempus beyond oncology into cardiovascular screening.

What critics are saying

  • Farrier et al. v. Tempus AI, filed April 15, 2026, attacks its genetic-data practices.
  • Personalis acquisition closes late 2026 or early 2027, risking integration failure and distraction.
  • Tempus still depends on reimbursement-heavy diagnostics; xF approval delays would crush 2028 upside.

What makes Tempus unique

  • Tempus combines oncology diagnostics, data licensing, and AI models across care pathways.
  • July 2026 xT Tumor Only made Tempus first FDA CDx holder for both CGP modes.
  • PRISM2 and AstraZeneca model wins show Tempus can translate datasets into usable products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Yahoo Finance
Aug 27th, 2026
Cathie Wood trims $4M stake in Tempus AI after 38% healthcare stock surge

Cathie Wood's Ark Investment Management sold $4 million worth of Tempus AI shares after the healthcare AI stock surged nearly 30% in recent days, making it the second-largest holding in her flagship fund. Wood sold 57,819 shares on 25 August, following Tempus AI's 38% rally since 18 August. The gains came after Merck and Moderna provided updates on a late-stage trial of their personalised cancer vaccine, for which Tempus plans to serve as the sequencing provider if approved. Tempus reported second-quarter revenue of $382.5 million, up 22% year-over-year, and raised its full-year revenue outlook to between $1.595 billion and $1.605 billion. The company also posted adjusted EBITDA of $8 million, compared with a $5.6 million loss the previous year. Wood's Ark Innovation ETF is up 10.16% year-to-date.

Associated Press
Aug 24th, 2026
Tempus receives FDA clearance for AI tool detecting pulmonary hypertension from ECGs

Tempus AI has received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled software that analyses standard 12-lead electrocardiograms to detect signs of pulmonary hypertension. This is the company's third FDA-cleared cardiovascular device. Pulmonary hypertension affects approximately 1% of the population and up to 10% of adults over 65, but remains difficult to diagnose. The condition is characterised by stiffening and narrowing of blood vessels in the lungs, straining the heart's right side. The software is designed for use on patients aged 40 and older with cardiovascular symptoms who have no known history of pulmonary hypertension. It detects signs associated with elevated mean pulmonary artery pressure. Tempus emphasises that the tool is not intended as a stand-alone diagnostic device and results must be interpreted alongside other clinical information.

SaasRise
Aug 23rd, 2026
Tempus AI executives dump $6.6M in shares ahead of 24% stock surge.

Tempus AI executives dump $6.6M in shares ahead of 24% stock surge. SaasRise - Aug 23, 2026 Tempus AI's CEO, CFO, diagnostics chief and several other insiders sold roughly $6.6 million of stock through pre-planned 10b5-1 trades between Aug 14-19. The sales occurred moments before the company's shares jumped 24% on Moderna and Merck trial news and a pending $1.5 billion Personalis acquisition, prompting investors to scrutinize governance and valuation. Why it matters. The Tempus AI insider sales episode illustrates how routine equity-compensation mechanics can be misread during periods of heightened market volatility. For SaaS investors, the episode raises red flags around governance transparency in companies that blend subscription revenue with high-margin, regulated services. The rapid price appreciation tied to external clinical trial results also shows how AI-native health-tech firms can experience valuation spikes that are not fully under their own operational control, emphasizing the need for investors to focus on underlying revenue growth, gross margin trends, and the execution of strategic acquisitions like Personalis. Moreover, the cluster of 10b5-1 trades underscores the importance of timing and communication. While the sales were pre-scheduled and tax-driven, the proximity to a 24% rally could fuel speculation about insider sentiment, potentially affecting future capital-raising efforts or employee morale. Companies in the SaaS space must therefore balance liquidity needs of executives with clear disclosure practices to maintain investor trust. Key points. * CEO Eric Lefkofsky sold ~133,000 shares for $6.6 M on Aug 18 at $49.61 avg price * CFO James Rogers sold 48,842 shares at $55.21 avg price; retains 106,000 shares * Total insider sell-to-cover volume across eight executives exceeded $6 M in a volatile week * Tempus reported Q2 GAAP profit of $5.6 M, revenue up 22% to $382.5 M, and raised FY guidance to $1.6 B * Stock jumped 24% on Aug 19 after Moderna/Merck trial news, validating Personalis acquisition Analysis. Tempus AI's recent insider activity is a textbook case of how 10b5-1 plans can intersect with market dynamics to create perception risk. The company's hybrid model - SaaS platform licensing paired with high-margin diagnostic testing - means its valuation is tethered both to recurring subscription metrics (ARR growth, net retention) and to episodic clinical milestones. The August rally was less about Tempus's own product rollout and more about external validation of the sequencing technology that underpins its pending Personalis deal. This creates a double-edged sword: while the trial news can catapult the stock, it also makes the share price vulnerable to any setback in the partner's pipeline. From an operator's perspective, the key takeaway is the necessity of decoupling growth narratives from one-off events. Tempus must demonstrate that its diagnostics revenue, now at $289 M, can sustain double-digit growth without relying on trial-driven hype. The data segment's 28% YoY expansion is promising, as it represents a higher-margin, SaaS-like revenue stream less exposed to reimbursement volatility. If the Personalis integration can unlock cross-selling opportunities and deepen the multimodal data repository, the company could solidify a defensible moat that justifies its $10.7 B market cap despite a $254 M net loss. Finally, the insider sales underscore a broader governance lesson for SaaS investors: transparency around equity-compensation timing is as critical as the financials themselves. While the 10b5-1 plans were properly disclosed, the clustering of sales around a dramatic price swing can seed doubt. Companies should consider augmenting standard filings with narrative guidance - especially when operating in high-visibility, regulated sectors - to reassure the market that insider actions are routine and not indicative of shifting confidence. In the coming quarters, Tempus's ability to sustain growth, integrate Personalis, and manage perception will determine whether the recent rally translates into lasting shareholder value.

Noah Business Intelligence
Aug 20th, 2026
Tempus AI lists on Nasdaq with $6B valuation as precision medicine platform gains momentum

Tempus AI, a Chicago-based precision medicine company, debuted on Nasdaq on 14 June 2024 with a valuation exceeding $6 billion. The company sells AI-powered tools across oncology, cardiology, radiology and depression, combining artificial intelligence with real-world clinical and molecular data to support personalised treatment decisions. Founded in 2015 by former Groupon chief executive Eric Lefkofsky, Tempus operates platforms including Hub, Lens and Next. The initial public offering was priced at the top of its range. The company argues that AI can identify patterns in large datasets to improve diagnosis and therapy selection. Its challenge lies in translating its data-driven approach into sustainable commercial performance across multiple medical disciplines.